Nasdaq:CNTA
Centessa Pharmaceuticals plc
A clinical-stage biopharma company advancing novel oncology and inflammation therapies with a robust $383.2M cash position but facing significant annual net losses.
Key Metrics
Investment Thesis
Bull Case
Investors might consider this stock as a high-risk, high-reward biotech play given its strong balance sheet with $383.2M in cash and equivalents that provides ample runway to advance its pipeline without immediate revenue pressure. The company's focus on serious unmet medical needs in oncology offers the potential for blockbuster-level returns if any of its clinical assets successfully gain regulatory approval and enter the market.
Bear Case
The investment case is severely weakened by a massive operating cash burn of $142.1M and an expanding retained earnings deficit of nearly $1B, suggesting the company may struggle to reach commercial milestones without further dilution or debt distress. With no meaningful revenue and zero gross profit, the business model relies entirely on successful clinical outcomes, which carries binary risk for shareholders.
About Centessa Pharmaceuticals plc
Centessa Pharmaceuticals plc is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapies for serious unmet medical needs, primarily in oncology and inflammation. The company operates globally with a strong pipeline of proprietary assets aimed at advancing through late-stage clinical development to commercialization. With minimal revenue from 2023 ($6.9M), the firm relies heavily on strategic financing and cash reserves to fund its R&D-intensive operations.
Analysis
Management Discussion
Despite a slight improvement in net loss from 2022 ($-216.2M) to 2023 ($-151.1M), Centessa experienced a significant deterioration in 2024 with a net profit of $-235.8M, indicating increasing burn rates as the company likely expanded its research teams or advanced clinical programs. The cash flow from financing remains highly positive at $364.8M, reflecting active capital raising efforts to offset the operating cash outflow of $142.1M and sustain operations.
Industry Overview
The global biopharmaceutical industry is currently navigating a period of consolidation where companies with promising late-stage pipelines are highly valued, while early-stage entities face intense pressure to demonstrate progress. Centessa operates in this competitive landscape aiming to bring novel small molecule therapies to patients with diseases that have limited treatment options.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $6.9M | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $6.9M | $0 |
| Operating Expenses | $212.3M | $178.1M | $201.1M |
| Operating Income | $-212.3M | $-171.3M | $-201.1M |
| G&A | $55.2M | $53.7M | $50.8M |
| Stock-Based Comp | $25.0M | $29.4M | $33.5M |
| D&A | $131.0K | $810.0K | $942.0K |
| Depreciation | — | $298.0K | $300.0K |
| Other OpEx | $157.1M | $124.4M | $150.2M |
| Non-Operating Income | $-4.7M | $-4.9M | $-31.9M |
| Interest Expense | — | $9.9M | — |
| Interest Income | — | — | $14.0M |
| Pre-Tax Income | $-217.0M | $-176.1M | $-232.9M |
| Income Tax | $-747.0K | $-25.1M | $2.8M |
| Continuing Ops | $-216.2M | $-151.1M | $-235.8M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-216.2M | $-151.1M | $-235.8M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-216.2M | $-151.1M | $-235.8M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $437.7M | $315.1M | $536.4M |
| Cash & Equivalents | $393.6M | $128.0M | $383.2M |
| Marketable Securities | — | $128.5M | $99.0M |
| Prepaid Expenses | $19.9M | $20.7M | $10.5M |
| Other Current Assets | $24.2M | $37.8M | $43.8M |
| Long-Term Assets | $6.6M | $45.2M | $40.4M |
| PP&E (Net) | $1.2M | $1.0M | $744.0K |
| Operating Leases | — | $11.9M | $11.0M |
| Other LT Assets | $5.4M | $32.2M | $28.6M |
| Total Assets | $444.3M | $360.2M | $576.8M |
| Current Liabilities | $38.3M | $39.4M | $58.0M |
| Accounts Payable | $13.8M | $11.8M | $7.1M |
| Current Leases | — | $505.0K | $602.0K |
| Taxes Payable | $1.6M | $112.0K | $835.0K |
| Other Current Liab | $-1.6M | $-617.0K | $-1.4M |
| Long-Term Liabilities | $69.8M | $84.6M | $117.3M |
| Long-Term Debt | $69.8M | $75.7M | $108.9M |
| LT Operating Leases | — | $8.9M | $8.3M |
| Other LT Liab | $0 | $29.0K | $29.0K |
| Total Liabilities | $108.1M | $124.0M | $175.3M |
| Shareholders' Equity | $336.2M | $236.2M | $401.5M |
| Paid-In Capital | $939.3M | $987.4M | $1.39B |
| Retained Earnings | $-601.9M | $-752.9M | $-988.7M |
| AOCI | $-1.5M | $1.5M | $4.2M |
| Total L&E | $444.3M | $360.2M | $576.8M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-216.2M | $-151.1M | $-235.8M |
| Non-Cash Adjustments | $-683.0K | $-5.2M | $85.4M |
| Working Capital Changes | $16.3M | $-4.0M | $8.3M |
| Cash from Operations | $-200.5M | $-160.3M | $-142.1M |
| Capital Expenditures | $1.1M | $169.0K | $34.0K |
| Cash from Investing | $-931.0K | $-127.0M | $31.3M |
| Cash from Financing | $457.0K | $21.1M | $364.8M |
| FX Effect | $-418.0K | $615.0K | $1.2M |
| Net Change in Cash | $-201.4M | $-265.6M | $255.2M |
| Beginning Cash | $595.1M | $393.6M | $128.0M |
| Ending Cash | $393.6M | $128.0M | $383.2M |
Frequently Asked Questions
How does Centessa Pharmaceuticals plc make money?
The company's financial structure indicates a pre-revenue or early commercial phase characterized by negligible cost of revenue and gross profit, suggesting operations are currently driven almost exclusively by research and development activities for its therapeutic pipeline rather than established product sales streams.
What are the main risks for CNTA?
The company faces substantial financial risk due to a net loss of $235.8M in 2024 and a cash flow from operations deficit of $142.1M, creating pressure on its limited liquidity reserves. Clinical trial failures for its pipeline assets could result in total write-offs and a complete loss of investor confidence in its development strategy. The company carries $108.9M in long-term debt against current liabilities of only $58.0M, raising potential solvency concerns if future financing rounds are not successful. Dependence on external equity or debt issuance is critical given the absence of meaningful revenue generation to cover operating expenses.
What is CNTA's competitive advantage?
Centessa possesses significant intellectual property protection through its proprietary small molecule technologies in oncology and inflammation, maintains a substantial cash runway exceeding $380 million to fund long-term clinical trials, and leverages an agile organizational structure typical of clinical-stage entities to accelerate asset development timelines.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.